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Gut/brain Axis and its Role in Parkinson’s Disease Progression 
by Kendra Myers 
 
Abstract  
The gut/brain access has a significant role in disease progression in Parkinson’s 
disease. There are several hypotheses for what is causing the progression itself; one of 
which is that the microbiome in the GI is creating SCFAs that are able to increase 
inflammation, -synuclein originates in the GI and is able to travel to the brain causing 
-synuclein aggregation and inflammation, and that the overall inflammation in the brain 
is causing activation of microglia causing increased -synuclein aggregation.  
It is unknown which of these is causing the disease, but they all have been shown to 
have a role. It is known that -synuclein aggregates cause motor symptoms and there is 
evidence to show that it originates from the dysbiosis of the GI microbiota. -synuclein 
in the CNS activates microglia cells, increasing proinflammatory cytokines TNF- and 
IL-6. The short chain fatty acids produced by fermentation byproducts of the gut 
microbiome play a role on the enteric nervous system and can be a major player of the 
nonmotor symptoms displayed by Parkinson’s disease patients and increasing 
inflammation. Lastly, the microbiome of Parkinson’s disease patients is altered from a 
normal gut microbiome to a disease-causing form.  All of these factors play a role in 
Parkinson’s disease progression but the main treatment (L-DOPA) does not directly 
impact any of these factors. 
 
Introduction 
Parkinson’s disease is the second 
leading neurological disease in adults 
over the age of 65 (Ganjavi et al., 2015). 
It is a multifactorial disease that is 
strongly influenced by environmental 
factors (Nalls et al., 2014). The 
pathological features of Parkinson’s are 
caused when dopaminergic neurons in 
the substantia nigra significantly restrict 
the supply of dopamine to the dorsal 
aspect of the striatum (Varanese et al., 
2010; Liddle, 2018; Ganjavi et al.2015). 
The reduction in functioning 
dopaminergic neurons is caused by the 
formation of Lewy bodies that are made 
by the presence of -synuclein 
(Liddle,2018). Alpha-synuclein is a 140 
amino acid protein that can form an 
incorrect structure and move from cell to 
cell, in a prion like fashion (Liddle, 
2018), causing other dopaminergic 
neurons to have this misfolded protein 
and lead to further loss of dopamine 
(Liddle, 2018). 
 
The loss of dopamine causes significant  
motor dysfunction (Varanese et al., 
2010; Ganjavi et al., 2015). Motor 
symptoms can be greatly improved with 
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the standard treatment of Levodopa 
(Ganjavi et al., 2015; Varanese et al., 
2010). The motor symptoms are 
treatable but only to an extent.  
Nonmotor symptoms of Parkinson’s are 
increasingly recognized cause of 
significant disability (Varanese et 
al.,2010; Ganjavi et al.,2015). These 
symptoms consist of dementia, 
psychosis, depression, anxiety, sleep 
disorders, dysphagia, and constipation 
(Varanese et al., 2010; Ganjavi et 
al.2015).  
 
Current Parkinson’s Treatment 
The discovery of Levodopa, L-3,4-
dihydroxyphenylalanine, (L-DOPA) by 
Arvid Carlson (Carlsson et al., 1957), 
has been the treatment of choice for 
therapeutic management of Parkinson’s 
disease. To this day L-DOPA is the 
most commonly used treatment due to 
its efficacy for relief in symptoms. Even 
though it is good at treating the 
symptoms there are still some major 
problems with the drug after the clinical 
benefit has been reached (Ganjavi et 
al., 2015). Some of these limitations are 
postural abnormalities, autonomic 
dysfunction, cognitive dysfunction, 
anxiety and drug-related side effects, 
such as L-DOPA-induced dyskinesia 
(LID) (Varanese et al.,2010; Ganjavi et 
al., 2015). LID occurs because of the 
dosage fluctuating between high and 
low due to oral dosing (Varanese et 
al.,2015). 
 
L-DOPA is usually given orally several 
times per day due to its relatively short 
half-life in plasma (Nutt, 2008). L-DOPA 
is also usually given with carbidopa, to 
prevent its conversion to dopamine in 
the peripheral nervous system allowing 
it to get to the central nervous system 
where L-DOPA is able to cross the 
blood brain barrier (Stansley and 
Yamamoto, 2015). Even though the 
increase in dopamine in the brain shows 
some improvement with symptoms, 
preclinical and clinical evidence 
suggests that L-DOPA treatment might 
be causing a worsening affect (Eskow 
Jaunarajs et al., 2012). The dopamine 
that is produced by L-DOPA is mediated 
in part by serotonin neurons and the 
increase of dopamine causes an 
oxidative stress that is damaging to 
serotonin neurons (Stansley and 
Yamamoto, 2015). L-DOPA is able to 
help with the symptoms of Parkinson’s 
but does not stop disease progression. 
 
Central nervous system 
The central nervous system is a very 
large network of neurons that is the 
command center for the entire body. 
The vagus nerve connects the enteric 
nervous system to the central nervous 
system. Since the vagus nerve goes 
from the brain to the abdominal area, 
regulates abdominal organ function. 
20% of the fibers are responsible for 
communication from the brain to the 
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ENS whereas the other 80% are for 
communication from the ENS to the 
brain (Figure 1, Breit et al., 2018). It is 
thought that -synuclein travels through 
the vagus nerve to get to the brain (Pan-
montojo et al., 2010). 
 
Enteric nervous system 
The GI tract consists of the enteric 
nervous system (ENS) made up of the 
myenteric and the submucosal plexi, 
these neurons are responsible for the 
smooth muscle relaxation and 
contraction and can be influenced by 
sympathetic and parasympathetic 
stimuli from the brain. The enteric 
nervous system and glial cells form a 
vast communication network that is in 
close proximity to the gut microbiome 
thus the enteric nervous system can be 
influenced by the bacteria in the gut 
(Caputi and Giron, 2018). This also 
means that the ENS can be affected by 
microbiome alterations. It is speculated 
that this could also be a cause of GI 
disorders and neurodegenerative 
disease. Therefore, the ENS can be a 
potential entry point for pathogens as 
well as therapeutic interventions based 
on diet and/or commensal microbiomes-
derived molecules (Endres and Schäfer, 
2018). 
 
 
Figure 1. Basic anatomy and function of the gut/brain access (Breit et al., 2018). This shows that the 
vaugs nerve originates in the brain and projects to the GI system. In the vagus nerve 20% of the 
nerve fibers are used for communication from the brain to the GI system whereas the other 80% of 
these nerves are used for communication from the GI system to the brain. 
 
Figure 1. Basic anatomy and function 
of the gut/brain access (Breit et al.). 
This shows that the vaugs nerve 
originates in the brain and projects to 
the GI system. In the vagus nerve 20% 
of the nerve fibers are used for 
communication from the brain to the GI 
system whereas the other 80% of 
these nerves are used for 
communication from the GI system to 
the brain.
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Gut/brain access and the microbiome  
The gut/brain access is defined as the 
bidirectional communication between 
the central nervous system, autonomic 
nervous system, and enteric nervous 
system (CNS, ANS, ENS respectively) 
through the vagus nerve (Figure 1,Breit 
et al., 2018; Mayer et al., 2015; Caputi 
and Giron, 2018). The role of both 
commensal and pathogenic organisms, 
has been recognized to influence the 
gut-brain access (Grenham et al.,2011). 
The bacteria in the GI tract are able to 
influence the neurons in the GI tract as 
they can synthesize neurotransmitters 
and neuromodulators, for example 
serotonin, dopamine, and short-chin 
fatty acids (Mulak et al., 2015; Mayer et 
al., 2015). This cellular communication 
between the bacteria in the gut and 
neurons in the ENS, has led to 
speculation that this communication can 
be a drug delivery system to get a 
neurotransmitter to the CNS. 
  
Discussion 
Dysbiosis of microbiome 
Parkinson’s disease patients have an 
altered microbiome (Hasegawa et al., 
2015; Keshavarzian et al., 2015; 
Scheperjans et al., 2015). When 
samples of human gut microbiomes 
were taken and given to germ free (GF) 
mice, there was a direct correlation 
between the disease status of the 
human donor and disease outcome in 
the GF mice recipients (Figure 2, 
Sampson et al., 2018). The humanized 
mouse groups that received transplants 
from PD donors had very similar 
microbial communities when compared 
to each other, whereas the humanized 
mouse groups that received transplants 
from healthy donors had more diversity 
(Sampson et al., 2018). 
There was also an altered number of 
genera between PD transplanted 
animals compared to animals with 
transplants from healthy donors 
(Sampson et al., 2018). The change in 
microbial diversity in PD patients was 
found to have an increase in genetic 
diversity of Proteus sp., Bilophila sp., 
and Roseburia sp., but there was a loss 
of members in Lachnopiraceae, 
Rikenellacea, and 
Peptostreptococcaceae families as well 
as Butyricicoccus sp. (Sampson et al., 
2018). Furthermore animals with PD 
donor transplants had significantly 
altered short chain fatty acid profile with 
a lower concentration of acetate, and 
higher relative abundances of 
propionate and butyrate, when 
compared to animals that received 
transplants from healthy donors 
(Sampson et al., 2018). 
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Figure 2. The left column shows how the microbiome of the gastrointestinal tract influences disease 
progression when a typical microbiome is established. The middle column shows when no 
microbiota is established, and the animal is germ free. The last column shows when Parkinson's 
disease derived microbiota is established causing major motor disfunction.  (Sampson et.al, 2018) 
 
What is causing dysbiosis of the 
microbiome in Parkinson’s disease 
patients? Evidence suggests that 
specific pesticide exposure is able to 
impact the microbiome configuration 
causing a microbial imbalance (Ascherio 
and Schwarzschild, 2016). There is also 
speculation that -synuclein may act as 
an antimicrobial and is able to shape the 
microbiome (Sampson et al., 2018). 
Whatever the cause may be, the 
Parkinson’s microbiota is either missing 
or has reduced protective microbes, 
and/or has pathogenic bacteria causing 
the disease. The dysbiosis will cause a 
differential production of microbial 
molecules in the GI and metabolites 
produced by this unbalanced 
microbiome may enter blood circulation 
and reach the brain, impacting neural 
function. 
 
Short Chain Fatty Acids 
Gut bacteria are able to modulate 
microglia activation through production 
of microbial metabolites known as short 
chain fatty acids (Erny et al., 2015). 
These short chain fatty acids include 
acetic acid, propionic acid, and butyric 
acid (Smith et al. 2013). Short chain 
fatty acids  are able to cross the blood 
brain barrier and impact physiology of 
Figure 2. The left column shows 
how the microbiome of the 
gastrointestinal tract influences 
disease progression when a typical 
microbiome is established. The 
middle column shows when no 
microbiota is established and the 
animal is germ free. The last 
column shows when Parkinson's 
disease derived microbiota is 
established causing major motor 
disfunction.  (Sampson et.al)
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the cells in the CNS or they can impact 
nerves in the periphery, indirectly 
activating mature microglia by unknown 
mechanisms (Mitchell et al.,2011; Erny 
et al., 2015). They have been shown to 
cause worsening effects in animals that 
already show motor disfunction 
(Sampson et al., 2018). In the same 
study, germ free – -synuclein 
overexpressing mice (GF – ASO) that 
were treated with heat-killed bacteria 
and were fed with short chain fatty 
acids, also showed motor deficits 
(Sampson et al., 2018). However when 
short chain fatty acids along with an 
anti-inflammatory compound 
(minocycline) are fed to GF – ASO, they 
showed reduced TNF-  production, 
reduced -synuclein aggregates, and 
improved motor function (Sampson et 
al., 2018).  
 
Both Sampson et al. and Unger et. al., 
showed that there is a reduction of short 
chain fatty acids in fecal samples from 
mice (Sampson et al., 2018) and human 
(Unger et al., 2016) Parkinson’s disease 
microbiome. There was a significant 
reduction of acetate, propionate, and 
butyrate in the fecal samples. Butyrate 
interacts with the local colonic mucosa 
and ENS neurons, increasing colonic 
activity (Soret et al., 2010; Kidd and 
Schneider, 2010). Reversely, when 
butyrate concentrations are low it is 
associated with dysmotility causing 
constipation in patients (Yamada et al., 
2014).  
 
-synuclein Pathology 
The unregulated expression of -
synuclein in humans leads to an 
increased risk of Parkinson’s disease 
(Soldner et al., 2016). In Parkinson’s 
disease, motor deficits coincide with -
synuclein aggregation and Lewy body 
formation (Liddle, 2018; Sampson et al., 
2018). This occurs due to -synuclein 
aggregation in specific parts of the 
brain. The -synuclein aggregation is 
observed in caudoputamen and 
substantia nigra, found in the 
nigrostriatal pathway in the brain 
(Brettschneider et al., 2015; Sampson et 
al., 2018). In Sampson et al. they 
compared alpha synuclein 
overexpressing (ASO) animals to the 
GF-ASO animals, they found that GF-
ASO animals displayed less -synuclein 
aggregates (Sampson et al., 2018). 
They also found that there was a 
regional specificity for -synuclein 
aggregation (Sampson et al., 2018). 
There was more -synuclein 
aggregation in the specific pathogen 
free (SPF) animals than the GF-ASO 
animals in the frontal cortex but in the 
cerebellum there was no difference 
(Sampson et al., 2018). Therefore, the 
microbiota could regulate the different 
pathways that promote -synuclein 
aggregation, prevent the clearance of 
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insoluble protein aggregates or 
accomplish both simultaneously. 
 
Microglia activation 
The microbiota is able to regulate 
immune development in the CNS and -
synuclein aggregates to activate 
immune cells, including brain-resident 
microglia (Matcovitch-Natan et al., 2016; 
Kim et al., 2013; Sanchez-Guajardo et 
al., 2013; Erny et al., 2015). When the 
microglia are activated they undergo 
major morphological changes, the cell 
bodies transition from numerus 
branched extensions to round, 
amoeboid cells with fewer branches 
(Figure 3, Lecours et al. 2018; Erny et 
al., 2015). This change in the microglia 
leads to increases pro-inflammatory 
cytokine tumor necrosis factor -  (TNF-
) and interleukin-6 (IL-6) (Sampson et 
al., 2018). Both cytokines are increased 
in the brains of Parkinson’s disease 
patients (Mogi, Harada, Riederer, et 
al.,1994; Mogi, Harada, Kondo, et al., 
1994). The neuroinflammatory 
responses are region specific with 
increased microglia diameter and TNF- 
production in the frontal cortex but not 
the cerebellum (Sampson et al., 2018). 
This supports that the gut microbes can 
promote -synuclein aggregates within 
specific brain regions involved in 
disease.
 
Figure 3. Microglial alterations found in Parkinson’s disease pathophysiology. In healthy individuals 
the microglia function properly and have good projections. In Parkinson's patients there are four 
other possible microglial morphologies. The amoeboid morphology has short thick processes and 
causes increased inflammation, motility and phagocytosis. Stress-Primed is very sensitive to 
immune challenges. Dark has increased interactions with synapses and have extremely thin 
projections. Lastly, the Dystrophic has short twisted processes and has decreased surveillance and 
phagocytosis but increased inflammation. (Lecours et. al, 2018) 
Figure 3. Microglial alterations found in Parkinson’s disease pathoph siology. In 
healthy individuals the microglia function properly and have good projections. In 
Parkinson's patients there are four other possible microglial morphologies. The 
amoeboid morphology has short thick processes and causes increased 
inflammation, otility and phagocytosis. Stress-Primed is very sensitiv  to 
immun  challenges. Dark has incr ased i teractions with synapses and have 
extremely thin projections. Lastly, the Dystrophic has short twisted processes and 
has decreased surveillance and phagocytosis but increased inflammation. 
(Lecours Et. Al)
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Conclusion  
Even though Parkinson’s disease is 
classified as a neurodegenerative 
disease, the gut microbiome has many 
roles in the disease progression. This 
paper shows that there is evidence to 
support dysbiosis of the gut microbiome 
allows production of -synuclein 
aggregates in the brain. The dysbiosis 
also alters the concentrations of short 
chain fatty acid synthesis in the gut, 
which can lead to increased production 
of pro inflammatory cytokines. 
Inflammation has a role in the activation 
of microglia, which increases 
inflammation in the brain causing more 
activation in the brain and more damage 
(Figure 4). Since it was demonstrated, 
when the microbiome from a 
Parkinson’s disease patient is given to 
an animal then that animal develops 
motor deficits. Led to the thought that a 
probiotic specific for Parkinson’s 
disease that would be able to alter the 
gut microbiome back to a non-diseased 
state would be a potential area of 
research and treatment option. Another 
area of future research could be to look 
at the use of anti-inflammatory drugs in 
reducing inflammation and motor deficit. 
 
Figure 4. Parkinson’s disease pathogenesis. Environmental factors affect microbial community 
causing dysbiosis. The dysbiosis in the GI tract then has an effect on alpha-synuclein, short chain 
fatty acid synthesis and inflammation, with all of these factors compounding each other. It is thought 
that alpha-synuclein and some of the short chain fatty acids are able to migrate via the vagus nerve 
to the brain. When they arrive in the brain, alpha-synuclein and short chain fatty acids cause neuro 
inflammation activating microglia. The microglia become more active increasing inflammation and 
alpha-synuclein aggregation, causing Parkinson’s disease.  
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